Salvador Barbero et al. found that sequential administration of CDK4/6 inhibitors were able to block the proliferation of paclitaxel‐treated pancreatic ductal adenocarcinoma (PDAC) cells.7 Here, CDK4 is linked to pancreatic ductal adenocarcinoma.